• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

合并糖尿病与未合并糖尿病的高血压患者血压转归的患者及医生决定因素的分层建模:六项缬沙坦观察性研究对15282例可评估患者的汇总分析

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients.

作者信息

Ashy Noha, Nguyen Thanh-Nga, Denhaerynck Kris, Gharaibeh Mahdi, Alhossan Abdulaziz, Vancayzeele Stefaan, Brié Heidi, Aerts Ann, MacDonald Karen, Abraham Ivo

机构信息

College of Pharmacy, King Abdulaziz University, P.O. Box 80200, Jeddah 21589, Saudi Arabia.

Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, 1295 N Martin, Tucson, AZ 85721, USA.

出版信息

Int J Chronic Dis. 2017;2017:9842450. doi: 10.1155/2017/9842450. Epub 2017 Sep 25.

DOI:10.1155/2017/9842450
PMID:29142906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5632928/
Abstract

We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were applied to identify determinants of BP outcomes. Similar reductions in BP values and similar BP control rates were achieved in both groups after approximately 90 days of therapy. The modeling analyses identified several common and different patient- and physician-related determinants of BP outcomes for both groups, many of which are modifiable or clinically manageable. Through varying in terms of association and influence between the diabetic and nondiabetic groups, patient-related determinants included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related determinants included gender, years in practice, and hypertension management. In summary, in both diabetic and nondiabetic patients, the use of valsartan-centric treatment regimens in second- or later-line antihypertensive treatment is associated with significant reductions in BP level and improvement in BP control. The determinants identified in modeling provide guidance to clinicians in the common and differential management of hypertension in diabetic and nondiabetic patients.

摘要

我们汇总了6项与缬沙坦相关的研究数据,其中包括3658例糖尿病患者和11624例非糖尿病患者,以评估二线或后续缬沙坦治疗约90天后的血压结局。应用分层线性回归和逻辑回归来确定血压结局的决定因素。治疗约90天后,两组的血压值均有相似程度的降低,血压控制率也相似。模型分析确定了两组血压结局的几个常见和不同的患者及医生相关决定因素,其中许多因素是可改变的或临床上可管控的。患者相关决定因素在糖尿病组和非糖尿病组之间的关联和影响有所不同,包括年龄、高血压诊断时的血压、危险因素、缬沙坦治疗方案、联合抗高血压治疗及依从性;医生相关决定因素包括性别、从业年限和高血压管理。总之,在糖尿病和非糖尿病患者中,二线或后续抗高血压治疗中使用以缬沙坦为中心的治疗方案均与血压水平显著降低及血压控制改善相关。模型分析中确定的决定因素为临床医生对糖尿病和非糖尿病患者高血压的共性和差异管理提供了指导。

相似文献

1
Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients.合并糖尿病与未合并糖尿病的高血压患者血压转归的患者及医生决定因素的分层建模:六项缬沙坦观察性研究对15282例可评估患者的汇总分析
Int J Chronic Dis. 2017;2017:9842450. doi: 10.1155/2017/9842450. Epub 2017 Sep 25.
2
Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients.对患者和医生决定降压治疗效果的因素进行分层的性别分析:7 项前瞻性真实世界研究合并 17044 例患者的汇总分析。
Curr Med Res Opin. 2021 Mar;37(3):367-375. doi: 10.1080/03007995.2021.1877124. Epub 2021 Feb 8.
3
Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients.高血压合并症患者缬沙坦治疗后血压决定因素和结局的分层建模:包括 11999 例患者在内的六项前瞻性真实世界研究的汇总分析。
Curr Med Res Opin. 2021 Jan;37(1):1-8. doi: 10.1080/03007995.2020.1853082. Epub 2020 Dec 11.
4
Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).缬沙坦治疗高血压的有效性:患者特征分析及决定因素与结局的分层建模(PREVIEW研究)
Ann Pharmacother. 2009 May;43(5):849-61. doi: 10.1345/aph.1L576. Epub 2009 Apr 7.
5
Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study).氨氯地平-缬沙坦单片复方制剂的疗效:血压和总体心血管疾病风险结局的分层模型分析(EXCELLENT 研究)。
Ann Pharmacother. 2011 Jun;45(6):727-39. doi: 10.1345/aph.1P663. Epub 2011 Jun 10.
6
Hierarchical modeling of patient and physician determinants of blood pressure outcomes in adherent vs nonadherent hypertensive patients: pooled analysis of 6 studies with 14,646 evaluable patients.在依从性高血压患者和非依从性高血压患者中,血压结果的患者和医生决定因素的分层建模:6 项研究共 14646 例可评估患者的汇总分析。
J Clin Hypertens (Greenwich). 2013 Sep;15(9):663-73. doi: 10.1111/jch.12163. Epub 2013 Jul 12.
7
Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study).在接受缬沙坦治疗的有和无已确立心血管或肾脏疾病的患者中血压结局的建模(PREVIEW 研究)。
Arch Cardiovasc Dis. 2013 Mar;106(3):124-34. doi: 10.1016/j.acvd.2012.11.006. Epub 2013 Mar 26.
8
Patient- and physician-level determinants of blood pressure response to treatment in normal weight and overweight patients (the PREVIEW study).正常体重和超重患者血压治疗反应的患者和医生水平决定因素(PREVIEW 研究)。
Nutr Metab Cardiovasc Dis. 2013 Apr;23(4):314-22. doi: 10.1016/j.numecd.2011.06.005. Epub 2011 Sep 17.
9
Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study.二线缬沙坦治疗后的血压和总体心血管风险结局建模:BSCORE 研究。
Arch Cardiovasc Dis. 2011 Aug;104(8-9):428-34. doi: 10.1016/j.acvd.2010.12.005. Epub 2011 Feb 22.
10
Gender-specific, multi-level determinants of outcomes of antihypertensive treatment: a sub-analysis of the Belgian PREVIEW study.降压治疗结局的性别特异性、多层次决定因素:比利时 PREVIEW 研究的一项亚分析。
J Hum Hypertens. 2011 Jun;25(6):372-82. doi: 10.1038/jhh.2010.71. Epub 2010 Jul 15.

引用本文的文献

1
Physicians' clinical experience and its association with healthcare quality: a systematised review.医生的临床经验及其与医疗质量的关系:系统评价。
BMJ Open Qual. 2021 Nov;10(4). doi: 10.1136/bmjoq-2021-001545.

本文引用的文献

1
The hypertension, diabetes and chronic kidney disease triangle in Arab countries.
J Hum Hypertens. 2017 Jun;31(6):373-375. doi: 10.1038/jhh.2017.16. Epub 2017 Mar 23.
2
Predicting blood pressure outcomes using single-item physician-administered measures: a retrospective pooled analysis of observational studies in Belgium.使用医生单项目测量法预测血压结果:比利时观察性研究的回顾性汇总分析
Br J Gen Pract. 2015 Jan;65(630):e9-15. doi: 10.3399/bjgp15X683101.
3
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).2014 年成人高血压管理的循证指南:第八届联合国家委员会(JNC 8)任命的专家组报告。
JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
4
Hierarchical modeling of patient and physician determinants of blood pressure outcomes in adherent vs nonadherent hypertensive patients: pooled analysis of 6 studies with 14,646 evaluable patients.在依从性高血压患者和非依从性高血压患者中,血压结果的患者和医生决定因素的分层建模:6 项研究共 14646 例可评估患者的汇总分析。
J Clin Hypertens (Greenwich). 2013 Sep;15(9):663-73. doi: 10.1111/jch.12163. Epub 2013 Jul 12.
5
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2013年欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)动脉高血压管理指南:欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)动脉高血压管理特别工作组
Eur Heart J. 2013 Jul;34(28):2159-219. doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14.
6
Role of physician gender in drug therapy.
Handb Exp Pharmacol. 2012(214):183-208. doi: 10.1007/978-3-642-30726-3_10.
7
Diabetes and hypertension: the bad companions.糖尿病与高血压:一对坏搭档。
Lancet. 2012 Aug 11;380(9841):601-10. doi: 10.1016/S0140-6736(12)60987-8.
8
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.缬沙坦对高血压和总体心血管风险的真实世界疗效:一项转化研究计划的综述与启示
Vasc Health Risk Manag. 2011;7:209-35. doi: 10.2147/VHRM.S9434. Epub 2011 Mar 31.
9
Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study).阿利吉仑在高血压“真实世界”管理中的降压疗效:180 天血压结局的多层次建模(比利时 DRIVER 研究)。
Int J Clin Pract. 2011 Jan;65(1):54-63. doi: 10.1111/j.1742-1241.2010.02562.x.
10
Systematic review: the relationship between clinical experience and quality of health care.系统评价:临床经验与医疗质量之间的关系
Ann Intern Med. 2005 Feb 15;142(4):260-73. doi: 10.7326/0003-4819-142-4-200502150-00008.